Chimin(SH:603222) Zheng Quan Ri Bao·2025-10-30 23:13Core Viewpoint - The company, Jimin Health, has announced its third-quarter financial report for 2025, highlighting its share repurchase plan and ongoing legal issues related to a fraud case involving a former employee [5][6]. Financial Data - The financial report for the first nine months of 2025 is unaudited, with no profits reported from merged entities [7][8]. - As of September 30, 2025, the company has repurchased 2,005,500 shares, totaling 12.089 million yuan (excluding transaction fees) [6]. Share Repurchase Plan - The company plans to repurchase shares using its own funds, with a maximum price of 10.00 yuan per share and a total repurchase amount between 100 million yuan and 200 million yuan, to be completed within 12 months from the board's approval [5]. Legal Issues - The company is currently facing 14 lawsuits from primary distributors involving 69.5026 million yuan and 10 lawsuits from secondary distributors involving 17.0766 million yuan due to a fraud case involving a former employee [6].